

No. 23-5110

**UNITED STATES COURT OF APPEALS
FOR THE TENTH CIRCUIT**

PETER POE, by and through his parents and next friends,
PAULA POE and PATRICK POE, *et al.*,
Plaintiffs-Appellants,

v.

GENTNER DRUMMOND, in his official capacity
as Attorney General of the State of Oklahoma, *et al.*,
Defendants-Appellees.

On Appeal from the United States District Court
for the Northern District of Oklahoma in Case No. 4:23-cv-00177
Before the Honorable John F. Heil, III

**BRIEF OF FOREIGN NON-PROFIT ORGANIZATIONS ADVOCATING
FOR THE RIGHTS OF TRANSGENDER PEOPLE AS AMICI CURIAE
IN SUPPORT OF PLAINTIFFS-APPELLANTS AND REVERSAL**

ANDREW RHYS DAVIES
CHARLES C. BRIDGE
EMILY BRODY-BIZAR
ANNA MIZZI
DUY NGUYEN
WILMER CUTLER PICKERING
HALE AND DORR LLP
7 World Trade Center
250 Greenwich Street
New York, NY 10007
(212) 230-8800
andrew.davies@wilmerhale.com

November 16, 2023

10th CIR. FORM 4. DISCLOSURE STATEMENT

UNITED STATES COURT OF APPEALS
FOR THE TENTH CIRCUIT

Fed. R. App. P. 26.1 and Tenth Circuit Rule 26.1 Disclosure Statement

Peter Poe, by and through his parents and next friends, **Paula Poe** and **Patrick Poe**, *et al.*,

v.

Gentner Drummond, in his official capacity as Attorney General of the State of Oklahoma, *et al.*,

Case No. 23-5110

Pursuant to Federal Rule of Appellate Procedure 26.1(a), (b), and/or (c), the undersigned, on behalf of Stonewall Equality Limited and 10 additional foreign non-profit organizations (see Addendum, Appendix A)

certifies¹ as follows:

- The following parent corporation(s); publicly held corporation(s); organizational victim(s); and/or debtor(s) are disclosed as required by Fed. R. App. P. 26.1 (attach additional pages if necessary):

- There is no information to disclose pursuant to Fed. R. App. P. 26.1.

November 16, 2023

Date

/s/ Andrew Rhys Davies

Signature

¹ Pursuant to Federal Rule of Appellate Procedure 26.1(d)(3), this disclosure statement must be promptly updated whenever any of the information required under Fed. R. App. P. 26.1 changes.

Appendix A – Addendum to FRAP 26.1 Statements
List of Amici Curiae Foreign Non-Profit Organizations

Poe v. Drummond, No. 23-5110

- (1) Stonewall Equality Limited
- (2) the Swedish Federation for Lesbian, Gay, Bisexual, Transgender, Queer and Intersex Rights (“RFSL”)
- (3) RFSL Ungdom
- (4) Transammans
- (5) Seta ry / Seta rf / Seta Lgbtiq Rights in Finland
- (6) the Norwegian Organization for Sexual and Gender Diversity
- (7) the Australian Professional Association for Trans Health
- (8) Bundesverband Trans* e.V.
- (9) the Fundación Colectivo Hombres XX, AC
- (10) the Professional Association for Transgender Health Aotearoa New Zealand
- (11) the Federación Estatal de Lesbianas, Gais, Trans, Bisexuales, Intersexuales y más

TABLE OF CONTENTS

	Page
CORPORATE DISCLOSURE STATEMENT	i
TABLE OF AUTHORITIES	iv
INTEREST OF AMICI CURIAE	1
SUMMARY OF ARGUMENT	2
ARGUMENT	4
I. TRANSGENDER ADOLESCENTS HAVE ACCESS TO APPROPRIATE GENDER-AFFIRMING HEALTHCARE IN THE UNITED KINGDOM, FINLAND, SWEDEN, AND NORWAY	4
A. United Kingdom	5
B. Finland	10
C. Sweden	12
D. Norway	14
II. GENDER-AFFIRMING HEALTHCARE IS AVAILABLE TO ADOLESCENTS IN OTHER DEVELOPED COUNTRIES	15
A. Australia	16
B. Germany	18
C. Mexico	19
D. New Zealand	20
E. Spain	22
CONCLUSION	23
CERTIFICATE OF COMPLIANCE	
ADDITIONAL CERTIFICATIONS	
APPENDIX A	
CERTIFICATE OF SERVICE	

TABLE OF AUTHORITIES

CASES

	Page(s)
<i>Bell v. Tavistock & Portman NHS Foundation Trust</i> , [2021] EWCA 1363 (Civ)	9, 10
<i>Gillick v. West Norfolk & Wisbech Health Authority</i> , [1986] 1 AC 112 (HL)	9
<i>Re Imogen</i> (No. 6), [2020] FamCA 761 (Austl.).....	17, 18
<i>Re J (An Infant): B & B v. Director-General of Social Welfare</i> , [1996] 2 NZLR 134 (N.Z.)	20
<i>Secretary, Department of Health & Community Services v. JWB & SMB</i> , (1992) 175 CLR 218 (Austl.)	17

STATE LEGISLATIVE MATERIALS

Oklahoma Senate Bill 613 (May 1, 2023) (codified Okla. Stat. tit. 63 § 2607.1), http://webserver1.lsb.state.ok.us/cf_pdf/2023-24%20ENR/SB/SB613%20ENR.PDF	2
--	---

FOREIGN LEGISLATIVE MATERIALS

Care of Children Act 2004, Public Act 2004 No. 90, https://legislation.govt.nz/act/public/2004/0090/latest/DLM317233.html	20
Spain Law 2/2016 (July 1, 2016).....	22
Spain Law 8/2016 (May 27, 2016)	22
Spain Law 4/2023, B.O.E. No. 51, art. 16 (Mar. 1, 2023), https://www.boe.es/buscar/act.php?id=BOE-A-2023-5366&p=20230301&tn=1#a1-8	23
Sveriges Riksdag, Health and Medical Services Act (2017), SFS No. 2017:30 (Swed.), https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/halso--och-sjukvardslag-201730_sfs-2017-30	13

OTHER AUTHORITIES

- AusPATH, *Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents* (Nov. 2020), https://www.rch.org.au/uploadedFiles/Main/Content/adolescent-medicine/230242%20RCH%20Gender%20Standards%20Booklet%201.4_Nov%202023_WEB.pdf 16, 17
- COHERE Finland, *Background Memorandum and Recommendations*, https://palveluvalikoima.fi/documents/1237350/22895008/Valmisteluistio_sukupuoli-identiteetin+variaatiot.pdf/991c7413-3bd5-3e9d-52c4-24c4e2a7a9e5/Valmisteluistio_sukupuoli-identiteetin+variaatiot.pdf (last visited Nov. 15, 2023)..... 11, 12
- COHERE Finland, *Recommendations*, https://palveluvalikoima.fi/documents/1237350/22895008/Alaik%C3%A4isetsuositus.pdf/c987a74c-dfac-d82f-2142-684f8ddead64/Alaik%C3%A4iset_suositus.pdf?t=1592317701000 (last visited Nov. 15, 2023)..... 12
- FRA European Union Agency for Fundamental Rights, *Access to Sex Reassignment Surgery*, <https://fra.europa.eu/en/publication/2017/mapping-minimum-age-requirements-concerning-rights-child-eu/access-sex-reassignment-surgery> (last visited Nov. 15, 2023) 23
- FRA European Union Agency for Fundamental Rights, *Access to Transgender Hormone Therapy*, <https://fra.europa.eu/en/publication/2017/mapping-minimum-age-requirements-concerning-rights-child-eu/access-transgender-hormone-therapy> (last visited Nov. 15, 2023) 22
- Government of Mexico, Secretary of Health, *Protocolo para el Acceso sin Discriminación a la Prestación de Servicios de Atención Médica de las Personas Lésbico, Gay, Bisexual, Transexual, Travesti, Transgénero e Intersexual y Guías de Atención Específicas* (2020), https://www.gob.mx/cms/uploads/attachment/file/558167/Versi_n_15_DE_JUNIO_2020_Protocolo_Comunidad_LGBTTI_DT_Versi_n_V_20.pdf..... 19, 20

Government Offices of Sweden, Ministry of Health & Social Affairs, *Every Child in Sweden Has the Right to a Safe, Secure and Bright Future* (July 25, 2023), <https://government.se/articles/2023/07/every-child-in-sweden-has-the-right-to-a-safe-secure-and-bright-future>..... 13

Helsedirektoratet, *Gender Incongruence*, <https://www.helsedirektoratet.no/retningslinjer/kjonnsinkongruens> (last visited Nov. 15, 2023) 15

Mahfouda, Simone, et al., *Puberty Suppression in Transgender Children and Adolescents*, 5 *Lancet Diabetes & Endocrinology* 816 (2017), <https://www.sciencedirect.com/science/article/pii/S2213858717300992?via%3Dihub#!> 17

New Zealand Ministry of Health, *Response to Your Request for Official Information* (Apr. 27, 2023), https://www.health.govt.nz/system/files/documents/information-release/h2023022566_response_letter.pdf 21, 22

New Zealand Ministry of Health, *Response to Your Request for Official Information* (June 1, 2023), https://www.health.govt.nz/system/files/documents/information-release/h2023024782_response_-_proactive_release.pdf 22

NHS England, *Gender Dysphoria – Treatment*, <https://www.nhs.uk/conditions/gender-dysphoria/treatment/> (last visited Nov. 15, 2023) 7

NHS England, *Interim Service Specification* (June 9, 2023), <https://www.england.nhs.uk/wp-content/uploads/2023/06/Interim-service-specification-for-Specialist-Gender-Incongruence-Services-for-Children-and-Young-People.pdf> 6, 7

NHS Standard Contract for Gender Identity Service for Children and Adolescents (Dec. 30, 2019), <https://www.england.nhs.uk/wp-content/uploads/2017/04/gender-development-service-children-adolescents.pdf>, *as amended*, Amendments to Service Specification for Gender Identity Development Service for Children and Adolescents (Oct. 6, 2021), <http://qna.files.parliament.uk/qna-attachments/1258355/original/HL11064-Amendment-to-Gender-Identity-Development-Service-Specification-for-Children-and-Adolescents.pdf>6

NICE, *Evidence Review: Gonadotrophin Releasing Hormone Analogues for Children and Adolescents with Gender Dysphoria* (2021), https://segm.org/sites/default/files/20210323_Evidence%2Breview_GnRH%2Banalogues_For%2Bupload_Final_download.pdf7, 8

Oliphant, Jeannie, et al., *Guidelines for Gender Affirming Healthcare for Gender Diverse and Transgender Children, Young People and Adults in Aotearoa New Zealand*, Transgender Health Research Lab, University of Waikato (Oct. 2018), <https://researchcommons.waikato.ac.nz/bitstream/handle/10289/12160/Guidelines%20for%20Gender%20Affirming%20Health%20low%20res.pdf>21

Oslo kommune, *Health Center for Gender and Sexuality*, <https://www.oslo.kommune.no/helse-og-omsorg/helsetjenester/helsestasjon-og-vaksine/helsestasjon-for-ungdom-hfu/helsestasjon-for-kjonn-og-seksualitet-hks/#gref> (last visited Nov. 15, 2023) 15

Oslo universitetssykehus, *Gender Incongruence*, <https://oslo-universitetssykehus.no/behandlinger/kjonnsinkongruens-utredning-og-behandling-av-barn-og-unge-under-18-ar> (last visited Nov. 15, 2023) 15

Press Release, *German Ethics Council Publishes Ad Hoc Recommendation on Trans Identity Among Children and Young People* (Feb. 20, 2020), <https://www.ethikrat.org/mitteilungen/mitteilungen/2020/deutscher-ethikrat-veroeffentlicht-ad-hoc-empfehlung-zu-trans-identitaet-bei-kindern-und-jugendlichen> 18, 19

Socialstyrelsen, *Care of Children and Adolescents with Gender Dysphoria* (Dec. 2022), <https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/kunskapsstod/2023-1-8330.pdf>.....13, 14

Socialstyrelsen, *God vård av barn och ungdomar med könsdysfori (Good care of children with gender dysphoria)* (Apr. 2015), <https://etik.barnlakarforeningen.se/wp-content/uploads/sites/16/2022/03/1.-SoS-God-va%CC%8Ard-av-barn-....pdf>14

The Cass Review, *The Independent Review of Gender Identity Services for Young People: Interim Report*, NHS (Feb. 2022), <https://cass.independent-review.uk/publications/interim-report>.....8, 9

INTEREST OF AMICI CURIAE¹

Amici curiae (1) Stonewall Equality Limited; (2) the Swedish Federation for Lesbian, Gay, Bisexual, Transgender, Queer and Intersex Rights (“RFSL”); (3) RFSL Ungdom; (4) Transammans; (5) Seta ry / Seta rf / Seta Lgbtiq Rights in Finland; (6) the Norwegian Organization for Sexual and Gender Diversity; (7) the Australian Professional Association for Trans Health; (8) Bundesverband Trans* e.V.; (9) the Fundación Colectivo Hombres XX, AC; (10) the Professional Association for Transgender Health Aotearoa New Zealand; and (11) the Federación Estatal de Lesbianas, Gais, Trans, Bisexuales, Intersexuales y más (collectively, the “Amici Organizations”) are non-profit organizations dedicated in whole or in part to securing and protecting the rights of transgender people. The Amici Organizations respectfully submit this brief to assist the Court in understanding the availability of gender-affirming healthcare for adolescents in each of the Amici Organizations’ respective home countries.

A more detailed statement of interest for each of the Amici Organizations is included in Appendix A.

¹ All parties have consented to the filing of this amicus brief. No counsel for a party authored any part of this brief, and no person other than amici curiae, their members, and their counsel made a monetary contribution to the preparation or submission of the brief.

SUMMARY OF ARGUMENT

Earlier this year, Oklahoma enacted a statute, Senate Bill 613, that prohibits gender-affirming healthcare for adolescents (the “State Healthcare Ban”). *See* Okla. Stat. tit. 63 § 2607.1; Appellants’ Br. 8-9. The District Court denied Plaintiffs’ motion for a preliminary injunction barring the enforcement of the State Healthcare Ban. This Court should reverse that order, recognizing (as the District Court did not) that this damaging and intrusive act of legislative overreach is likely unconstitutional and poses an acute risk of imminent harm to Plaintiffs-Appellants if permitted to take effect.

In defense of the State Healthcare Ban, Oklahoma—as well as some of its amici²—has claimed that the legislation finds support in recent actions taken in certain European countries regarding the treatment of transgender adolescents. Specifically, they have pointed to some assessments of existing research con-

² One amicus brief filed in the District Court asserts that “[h]ealth authorities in Sweden, Finland, and the United Kingdom have conducted systematic reviews of evidence and ... have decided to place severe restrictions on medical transition procedures—generally limiting the use of these treatments to research studies.” Do No Harm and Okla. Council of Pub. Affairs Amici Br. 9, Dist. ECF No. 102-1. Another amicus brief asserts that “medical authorities in the UK, Finland, Sweden, and Norway have all looked at the evidence and determined that transitioning treatments for minors are experimental.” Brief of Amici Arkansas, Alabama, et al. in Support of Defs.’ Opp. to Mot. for Preliminary Injunction (“Amici States Dist. Ct. Br.”) at 2, Dist. ECF No. 78-1.

ducted by certain European governmental and nongovernmental bodies, and to changes in practices adopted regarding the provision of care.

These reports and practices, however, neither amount to nor support a ban on gender-affirming treatment for transgender adolescents. And the assertions by Oklahoma and its amici about the approach that other developed countries are taking to the provision of gender-affirming healthcare to transgender adolescents are not correct—or, at a minimum, are exaggerated and misleading, and presented without vitally important context. In truth, the State Healthcare Ban is an outlier when viewed against a global backdrop. In each of the countries that Oklahoma and its amici have referenced, care continues to be provided to adolescents who need it. The State Healthcare Ban, and the many similar laws recently enacted elsewhere in the United States, is thus inconsistent with international practices.

The Amici Organizations submit this brief to ensure that the Court has the benefit of accurate information about the gender-affirming healthcare that is available to adolescents in foreign countries that Oklahoma and its amici have referenced: Sweden, the United Kingdom, Finland, and Norway. This brief also provides information about the availability of gender-affirming healthcare to transgender adolescents in several other developed countries: Australia, Germany, Mexico, New Zealand, and Spain.

In all the countries surveyed below, adolescent patients—together with their physicians and their parents or legal guardians—make decisions about whether gender-affirming healthcare is appropriate. And in all those countries, when medically appropriate, adolescent patients have access to treatment that is prohibited by the State Healthcare Ban. These foreign sovereigns leave these important decisions principally to patients, their families, and the medical community—not to lawmakers enacting blanket prohibitions on entire categories of medical treatments.

The Court should reverse and remand with instructions to enter a preliminary injunction.

ARGUMENT

I. TRANSGENDER ADOLESCENTS HAVE ACCESS TO APPROPRIATE GENDER-AFFIRMING HEALTHCARE IN THE UNITED KINGDOM, FINLAND, SWEDEN, AND NORWAY

In the District Court, Oklahoma and its amici cited materials referencing the United Kingdom, Finland, Sweden, and Norway in support of a ban on gender-affirming healthcare for minors.³ Although some assessments of the existing

³ See Defs. 15-53’s Response to Pls.’ Mot. for Preliminary Injunction (“State Defs.’ Dist. Ct. Opp.”) at 12-14, Dist. ECF No. 86; Amici States Dist. Ct. Br. 2-4.

Oklahoma’s brief also mentions in passing the Netherlands, *see* State Defs.’ Dist. Ct. Opp. 13-14, but only to quote a magazine article for the proposition that unspecified “[d]oubts have now come to the Netherlands” with respect to the

research performed in these European countries have recommended certain changes to how medical care is delivered to transgender adolescents, the governments in those countries—unlike Oklahoma’s—have not prohibited clinicians from treating their patients. In all four of those countries, and in many other developed nations around the world, transgender adolescents have access, when needed, to appropriate gender-affirming healthcare, including care that the State Healthcare Ban prohibits.

A. United Kingdom

Appellees and the Amici States present an incorrect and incomplete picture of transgender adolescents’ access to gender-affirming healthcare in the United Kingdom, portraying the United Kingdom as banning care except for “limited,” “experimental” settings. State Defs.’ Dist. Ct. Opp. 12-13, 17; *see also* Amici States Dist. Ct. Br. 2-3 (describing the United Kingdom as one of several European countries that has purportedly “determined that transitioning treatments for minors are experimental.”).

First, Appellees and the Amici States portray gender-affirming care as “experimental,” *e.g.*, Amici States Dist. Ct. Br. 2-3, incorrectly stating that “puberty blockers will only be used in clinical trials,” State Defs.’ Dist. Ct. Opp.

medically appropriate standards for gender-affirming care—not to suggest that the Netherlands has restricted or banned treatment for transgender adolescents.

12-13. But the fact that adolescents, to access free hormone therapy from the NHS, will be enrolled in “formal research protocol[s]”⁴ does not indicate that the treatment is “experimental”—nor does it render the treatment’s benefits any less meritorious. It shows only that the United Kingdom is doing precisely what the Appellees purport to believe should occur: developing more data to drive evidence-based policies.⁵ Developing a body of evidence to support medical decisions informed by scientific study is an entirely reasonable approach—and is far from a ban on treatment.

Moreover, Appellees ignore that the policies they reference apply only to the United Kingdom’s publicly funded National Health Service (the “NHS”). There is no ban on gender-affirming healthcare for adolescents in the United Kingdom; the very policy Appellees reference as asserting “puberty blockers will only be used in clinical trials,” State Defs.’ Dist. Ct. Opp. 13, actually contemplates adolescents coming into the NHS’s care after having already received puberty blockers and/or

⁴ NHS England, *Interim Service Specification* 16-18 (June 9, 2023), <https://www.england.nhs.uk/wp-content/uploads/2023/06/Interim-service-specification-for-Specialist-Gender-Incongruence-Services-for-Children-and-Young-People.pdf>.

⁵ *See generally* NHS Standard Contract for Gender Identity Service for Children and Adolescents (Dec. 30, 2019), <https://www.england.nhs.uk/wp-content/uploads/2017/04/gender-development-service-children-adolescents.pdf>, *as amended*, Amendments to Service Specification for Gender Identity Development Service for Children and Adolescents (Oct. 6, 2021), <http://qna.files.parliament.uk/qna-attachments/1258355/original/HL11064-Amendment-to-Gender-Identity-Development-Service-Specification-for-Children-and-Adolescents.pdf>.

hormone therapy from a private physician.⁶ The NHS’s webpage of information on Treatment of Gender Dysphoria includes information on hormone therapy for adolescents.⁷

Appellees, through Dr. Cantor, and the Amici States also misconstrue the review by the U.K. National Institute for Health and Care Excellence (“NICE”), from which they quote selectively. *See* State Defs.’ Dist. Ct. Opp. 12-13 (citing Ex. 1, Cantor Expert Report, Dist. ECF No. 86-1); Amici States Dist. Ct. Br. 2-3. Although NICE concluded that the evidence of the effectiveness of treatment with puberty blockers was of “very low certainty” under the GRADE rating system,⁸ the report recommended that gender dysphoria should be treated with “management plans [that] are tailored to the needs of the individual.”⁹ According to NICE, such treatment plans may include “psychological support and exploration and, for some individuals, the use of GnRH analogues [i.e., puberty blockers] in adolescence to

⁶ NHS England, *Interim Service Specification* 16-18, *supra* note 4.

⁷ *See* NHS England, *Gender Dysphoria – Treatment*, <https://www.nhs.uk/conditions/gender-dysphoria/treatment/> (last visited Nov. 15, 2023).

⁸ NICE, *Evidence Review: Gonadotrophin Releasing Hormone Analogues for Children and Adolescents with Gender Dysphoria* 4-6 (2021), https://segm.org/sites/default/files/20210323_Evidence%2Breview_GnRH%2Banalogues_For%2Bupload_Final_download.pdf.

⁹ *Id.* at 3.

suppress puberty; this may be followed later with gender-affirming hormones of the desired sex.”¹⁰

Moreover, the NHS’s recent Interim Report makes clear that gender-affirming healthcare should be available to adolescents in the United Kingdom when appropriate. To be sure, the Interim Report urges caution, and states that “clinical services must be run as safely and effectively as possible, within the constraints of current knowledge,” and that “treatment options must be weighed carefully.”¹¹ Unlike Oklahoma, however, the NHS’s Interim Report acknowledges that “treatment decisions must be made in partnership between the clinicians and the children, young people and their families and carers, based on our current understanding about outcomes.”¹²

The Interim Report does not advocate for a ban on gender-affirming healthcare services for transgender adolescents. To the contrary, it calls for the immediate expansion and regionalization of services, so that patients under eighteen have access to a better quality of care closer to home, and with reduced

¹⁰ *Id.*

¹¹ The Cass Review, *The Independent Review of Gender Identity Services for Young People: Interim Report* 68, NHS (Feb. 2022), <https://cass.independent-review.uk/publications/interim-report> (select “Download the Interim report”).

¹² *Id.*

waiting time.¹³ As to puberty blockers in particular, the Interim Report again does not recommend a ban, but instead observes that it is especially important for an adolescent patient’s treating clinician to be able to demonstrate informed consent.¹⁴

This point about informed consent—which Oklahoma and the Amici States do not meaningfully address—is critical. In the United Kingdom, unlike in many U.S. jurisdictions, minors can validly consent to a medical procedure, provided that they have so-called *Gillick* competence. *See Gillick v. West Norfolk & Wisbech Health Auth.*, [1986] 1 AC 112 (HL). Under *Gillick*, a minor’s “capacity to make his or her own decision depends upon the minor having sufficient understanding and intelligence to make the decision,” without regard to any “judicially fixed age limit.” *Id.* ¶ 188B. It is not the role of the court to intercede into a clinician’s authority in determining whether to recommend treatment—or the decision of a competent minor in determining whether to undergo such treatment. *See id.*

Applying these principles, the Court of Appeal for England and Wales has established that an adolescent’s ability to consent to gender-affirming healthcare—like other healthcare—is a matter for adolescents and their clinicians and parents or legal guardians, not for the government. *Bell v. Tavistock & Portman NHS Found. Tr.*, [2021] EWCA 1363 (Civ), ¶¶ 86-87. In so holding, the Court of Appeal

¹³ *Id.* at 69-72.

¹⁴ *Id.* at 72.

roundly rejected a trial court’s conclusion in that case that adolescents under the age of sixteen were generally incapable of providing such consent and that judicial involvement in the medical decision-making process was therefore needed. *See id.* ¶¶ 91-94. The Court of Appeal acknowledged that the provision of gender-affirming healthcare is a complex topic, noting that clinicians should take “great care” before recommending gender-affirming treatment to an adolescent, *id.* ¶ 92, but concluded that, as far as a minor’s *Gillick* competence to consent to such care is concerned, “[n]othing about the nature or implications of the treatment with puberty blockers allows for a real distinction to be made” between that and any other medical treatment, *id.* ¶ 76. In the Court of Appeal’s judgment, “the [trial] court was not in a position to generalise about the capability of persons of different ages to understand what is necessary for them to be competent to consent to the administration of puberty blockers.” *Id.* ¶ 85. Likewise, Oklahoma and the Amici States are in no such position.

B. Finland

Oklahoma and the Amici States cite to recommendations promulgated by the Council for Choices in Health Care in Finland (“COHERE Finland”) in support of their position that uncertainty regarding treatment outcomes justifies Oklahoma’s actions here. *See State Defs.’ Dist. Ct. Opp.* 13; *Amici States Dist. Ct. Br.* 17. However, Oklahoma seeks to do something Finland has never done—ban

treatment—and Oklahoma and its Amici States misconstrue the contours of the COHERE Finland recommendations they cite.

COHERE Finland is a permanent body, appointed by the Government of Finland, that works in conjunction with Finland’s Ministry of Social Affairs and Health.¹⁵ In 2011, Finland created an avenue for adolescents to seek treatment for trauma caused by gender dysphoria. Although adolescents cannot access surgical treatment for gender dysphoria until age eighteen, they can begin the diagnostic process at age thirteen.¹⁶ COHERE Finland’s recommendations recognize a treatment protocol for transgender adolescents as part of the Finnish healthcare system. Patients whose puberty has not started, and who experience long term or severe gender dysphoria-related anxiety, can be sent for consultation at the university hospitals in Helsinki or Tampere.¹⁷ There, after conducting diagnostics to confirm medical necessity with no contraindications, clinicians can treat a

¹⁵ See COHERE Finland, *Background Memorandum and Recommendations*, https://palveluvalikoima.fi/documents/1237350/22895008/Valmistelumuistio_sukupuoli-identiteetin+variaatiot.pdf/991c7413-3bd5-3e9d-52c4-24c4e2a7a9e5/Valmistelumuistio_sukupuoli-identiteetin+variaatiot.pdf (last visited Nov. 15, 2023).

¹⁶ See *id.* at 16.

¹⁷ *Id.* at 7.

patient with puberty blockers upon the onset of puberty.¹⁸ It is also possible to access medication to block menstruation.¹⁹

COHERE Finland's recommendations also state that an adolescent who has already begun puberty can be referred to a university hospital for gender-affirming treatment if the patient's gender identity variation and related dysphoria appear stable over the long term.²⁰ Gender-affirming hormonal interventions can be prescribed for patients commencing at age sixteen, absent contraindications, if the patient's gender dysphoria is considered permanent and severe and the patient has the capacity to understand the impact of the non-reversible aspects of the treatment and the pros and cons of hormonal treatment.²¹

C. Sweden

Gender-affirming healthcare is available to adolescents on an individual basis in Sweden, and the Swedish government has not inserted itself into its citizens' medical decision-making, as Oklahoma has done by means of the State Healthcare Ban's prohibition on physicians' ability to provide medical treatment

¹⁸ *Id.* at 14, 17.

¹⁹ *Id.* at 16.

²⁰ *Id.* at 15.

²¹ *See* COHERE Finland, *Recommendations* 9, https://palveluvalikoima.fi/documents/1237350/22895008/Alaik%C3%A4isetsuositus.pdf/c987a74c-dfac-d82f-2142-684f8ddead64/Alaik%C3%A4iset_suositus.pdf?t=1592317701000 (last visited Nov. 15, 2023).

that they consider appropriate.²² While Sweden and its national health agency have updated the agency's non-binding medical recommendations, Sweden continues to permit individual patients to receive appropriate gender-affirming healthcare when a physician considers that course of treatment appropriate.

In Sweden, access to healthcare is governed by the Health and Medical Services Act.²³ Under the framework of that law, medical treatment is valid so long as it comprises treatment that can relieve or alleviate pain or illness. Gender-affirming healthcare, like all medical practice in Sweden, needs to be performed within the framework of the law, based on medical evidence and well-known practice. Sweden also adheres to the United Nations Convention on the Rights of the Child, which recognizes a child's right to have a say in their medical treatment, and that this right increases with age.²⁴

²² See Socialstyrelsen, *Care of Children and Adolescents with Gender Dysphoria* 4-5 (Dec. 2022), <https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/kunskapsstod/2023-1-8330.pdf>.

²³ Sveriges Riksdag, Health and Medical Services Act (2017), SFS No. 2017:30 (Swed.), https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/halso--och-sjukvardslag-201730_sfs-2017-30 (select "English" translation).

²⁴ Government Offices of Sweden, Ministry of Health & Social Affairs, *Every Child in Sweden Has the Right to a Safe, Secure and Bright Future* (July 25, 2023), <https://government.se/articles/2023/07/every-child-in-sweden-has-the-right-to-a-safe-secure-and-bright-future>.

For over twenty years, adolescent patients in Sweden have had access to gender-affirming healthcare. The Swedish National Board of Health and Welfare promulgates national guidelines to support clinicians in making decisions concerning the healthcare needs of their patients.²⁵ Since 2015, the guidelines have addressed hormone treatment for gender dysphoria. And although those guidelines were updated in 2022—to advise that hormone treatment should be “administered in exceptional cases” rather than at “a group level”—the guidelines still permit the use of puberty blockers and gender-affirming hormones on a case-by-case basis, and they emphasize the importance of young people with gender dysphoria continuing to receive care within the healthcare system.²⁶

D. Norway

In Norway, both puberty blockers and hormone therapy are available to adolescent patients, although surgical treatment is generally not available before the age of majority. Access to gender-affirming healthcare, including hormone therapy and mental health support, for adolescent patients is defined in the National Guidelines on the Treatment of Gender Incongruence, promulgated by the

²⁵ Socialstyrelsen, *God vård av barn och ungdomar med könsdysfori (Good care of children with gender dysphoria)* (Apr. 2015), <https://etik.barnlakarforeningen.se/wp-content/uploads/sites/16/2022/03/1.-SoS-God-va%CC%8Ard-av-barn-....pdf>.

²⁶ Socialstyrelsen, *Care of Children and Adolescents with Gender Dysphoria 3*, *supra* note 22.

Norwegian Directorate of Health.²⁷ Puberty blockers are administered to patients based on their pubertal development stage. Any patient over the age of sixteen may access puberty blockers and hormone therapy upon prescription by a clinician; parental consent is not required.

For adolescents under sixteen, puberty blockers are available with parental consent on a case-by-case basis after an evaluation by medical experts, either through the clinician specialist team at Oslo University Hospital or via a health service organized under the Municipality of Oslo which specializes in services for gender nonconforming and LGBTQI youth.²⁸

II. GENDER-AFFIRMING HEALTHCARE IS AVAILABLE TO ADOLESCENTS IN OTHER DEVELOPED COUNTRIES

A review of the status of transgender adolescents' access to gender-affirming healthcare in other countries reveals a common thread.²⁹ With

²⁷ See Helsedirektoratet, *Gender Incongruence*, <https://www.helsedirektoratet.no/retningslinjer/kjonnsinkongruens> (select “English” translation) (last visited Nov. 15, 2023).

²⁸ See Oslo universitetssykehus, *Gender Incongruence*, <https://oslo-universitetssykehus.no/behandler/kjonnsinkongruens-utredning-og-behandling-av-barn-og-unge-under-18-ar> (select “English” translation) (last visited Nov. 15, 2023); Oslo kommune, *Health Center for Gender and Sexuality*, <https://www.oslo.kommune.no/helse-og-omsorg/helsetjenester/helsestasjon-og-vaksine/helsestasjon-for-ungdom-hfu/helsestasjon-for-kjonn-og-seksualitet-hks/#gref> (select “English” translation) (last visited Nov. 15, 2023).

²⁹ Absent a French amicus organization, this brief does not address the situation in France. Appellees' own expert, however, acknowledges that “medical authorities in France have not issued any actual restriction” prohibiting clinicians

appropriate consultation and diagnoses and properly informed consent, transgender adolescents can access various forms of gender-affirming care, including treatment that the State Healthcare Ban prohibits.

A. Australia

The Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents (the “ASOCT Guidelines”), developed with available evidence and supported by AusPATH, recommend that, following a DSM-V diagnosis of gender dysphoria and comprehensive, developmentally appropriate medical and psychosocial assessment, clinicians prescribe puberty blockers, hormone treatment, and psychological support as appropriate where the patient agrees that hormone therapy or puberty blockers is in their best interest.³⁰ The ASOCT Guidelines rely on empirical evidence and clinical consensus and

from providing gender-affirming healthcare. Cantor Expert Report ¶ 29, ECF No. 86-1. On the contrary, France’s National Academy of Medicine (Académie Nationale de Médecine) contemplates that clinicians may provide such treatment, provided that they exercise “great medical caution” and explore alternative therapies as well. *Id.*

³⁰ See AusPATH, *Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents* 23-24 (Nov. 2020), https://www.rch.org.au/uploadedFiles/Main/Content/adolescent-medicine/230242%20RCH%20Gender%20Standards%20Booklet%201.4_Nov%202023_WEB.pdf.

were developed in consultation with professionals working with transgender and gender diverse communities across Australia and New Zealand.³¹

In Australia, a parent generally has power to consent to medical treatment, but the parental power to consent diminishes as the patient's capacities and maturities grow. *See Secretary, Dep't of Health & Cmty. Servs. v. JWB & SMB* (“*Marion's case*”), (1992) 175 CLR 218 (Austl.). The Australian High Court has adopted the *Gillick* competence framework, *see supra* pp. 9-10, holding that a minor is capable of giving informed consent, and a parent is no longer capable of consenting on the minor's behalf, when the minor achieves *Gillick* competence—that is, a sufficient understanding and intelligence to enable them to understand fully what treatment is proposed. *See Marion's case*, 175 CLR at 237 (Mason CJ, Dawson, Toohey and Gaudron JJ) (citing *Gillick*).

Legal access to gender-affirming healthcare for patients under eighteen was addressed in *Re Imogen* (No. 6), [2020] FamCA 761 (Austl.), in which the Australian Family Court held that adolescent patients can legally receive hormone

³¹ *See id.* at 2. Australia is also home to clinical research affirming the medical benefit of puberty blockers for transgender youth. For example, one published Australian study found that the available evidence, although limited, points to the safety of puberty blockers and the psychological benefits of suppressing puberty before the possible future commencement of hormone therapy. *See Mahfouda et al., Puberty Suppression in Transgender Children and Adolescents*, 5 *Lancet Diabetes & Endocrinology* 816, 819-820 (2017), <https://www.sciencedirect.com/science/article/pii/S2213858717300992?via%3Dihub#!>.

treatment if there is no dispute between parents (or those with parental responsibility), the medical practitioner, and the patient with regard to *Gillick* competence, the diagnosis of gender dysphoria, or the proposed treatment for alleviating the suffering caused by the gender dysphoria. *See id.* ¶ 35. Any such dispute requires an application to the Family Court. *Id.* ¶¶ 35, 38. But where the adolescent, their parents, and their clinician are all in agreement, care is available, and there are no governmental barriers.

B. Germany

Gender-affirming healthcare for transgender adolescents under the age of eighteen is available in various forms throughout Germany. German medical associations are developing guidelines for gender-affirming healthcare relating to teenage transgender patients.

In February 2020, the German Ethics Council addressed healthcare for transgender teenagers.³² The Council acknowledged the tension created by the potentially irreversible consequences of either administering treatment or withholding treatment, but its statement declared that it is not an option to limit access to gender-affirming healthcare for adolescents who understand the

³² Press Release, *German Ethics Council Publishes Ad Hoc Recommendation on Trans Identity Among Children and Young People* (Feb. 20, 2020), <https://www.ethikrat.org/mitteilungen/mitteilungen/2020/deutscher-ethikrat-veroeffentlicht-ad-hoc-empfehlung-zu-trans-identitaet-bei-kindern-und-jugendlichen> (select “English” translation).

consequences of their decision to undergo treatment.³³ The Council noted that where “the child is sufficiently capable of insight and judgement to understand the scope and significance of the planned treatment, to form his own judgement and to decide accordingly, his will must be decisively taken into account.”³⁴

C. Mexico

Transgender healthcare in Mexico is guided by the Protocol for Access without Discrimination to Health Care Services for Lesbian, Gay, Bisexual, Transsexual, Transvestite, Transgender, and Intersex Persons and Specific Care Guidelines.³⁵ The Protocol is observed in healthcare facilities administered by the Mexican federal government. The Protocol acknowledges that the process of defining one’s sexual orientation, gender identity and/or expression may occur at early stages.³⁶ The Protocol therefore advises that medical facilities start from a presumption of providing medical care where needed, and it recommends that clinicians consider the use of puberty blockers and hormone treatment when

³³ *Id.*

³⁴ *Id.*

³⁵ Government of Mexico, Secretary of Health, *Protocolo para el Acceso sin Discriminación a la Prestación de Servicios de Atención Médica de las Personas Lésbico, Gay, Bisexual, Transexual, Travesti, Transgénero e Intersexual y Guías de Atención Específicas* (2020), https://www.gob.mx/cms/uploads/attachment/file/558167/Versi_n_15_DE_JUNIO_2020_Protocolo_Comunidad_LGBTTI_DT_Versi_n_V_20.pdf.

³⁶ *Id.* at 35.

appropriate.³⁷ In addition to the Protocol, various Mexican states have reformed their civil codes to recognize the right to gender-affirming healthcare for transgender patients under eighteen.

D. New Zealand

In New Zealand, the Care of Children Act 2004 empowers adolescents aged sixteen and older to consent to medical care.³⁸ With respect to medical care generally, including gender-affirming care for transgender patients, adolescents under sixteen may consent to treatment if they meet the *Gillick* standard, *see supra* pp. 9-10, which the New Zealand Court of Appeal has cited with approval, *see Re J (An Infant): B & B v. Director-General of Social Welfare*, [1996] 2 NZLR 134 (N.Z.). Family support is, however, considered an important aspect of gender-affirming care for all adolescents in New Zealand, with families involved in care wherever possible.

New Zealand has provided gender-affirming healthcare to adolescents for over sixteen years. Clinicians in New Zealand also utilize the ASOCT Guidelines—developed, as noted above, with the help of New Zealand adolescent-health clinicians. *See supra* pp. 17-18. New Zealand’s current national guidelines

³⁷ *Id.* at 36.

³⁸ Care of Children Act 2004, Public Act 2004 No. 90, <https://legislation.govt.nz/act/public/2004/0090/latest/DLM317233.html>.

for gender-affirming healthcare for gender diverse and transgender patients were published in 2018; they allow for puberty blockers to be prescribed depending on the stage of puberty, and also allow for hormone treatment.³⁹

In September 2022, New Zealand’s Ministry of Health altered certain language on its website relating to puberty blockers.⁴⁰ The update “recognised that overseas jurisdictions, including [the United Kingdom], Norway and Sweden, were reviewing the use of puberty blockers in their health systems particularly in younger people,” and that “any medical intervention carries a balance of benefit and risk that needs to be considered in context by the person in partnership with their health professional.”⁴¹ But the Ministry of Health has since reaffirmed that “[i]t is important that health services meet the needs of all New Zealanders, with

³⁹ Oliphant et al., *Guidelines for Gender Affirming Healthcare for Gender Diverse and Transgender Children, Young People and Adults in Aotearoa New Zealand* 29-31, Transgender Health Research Lab, University of Waikato (Oct. 2018), <https://researchcommons.waikato.ac.nz/bitstream/handle/10289/12160/Guidelines%20for%20Gender%20Affirming%20Health%20low%20res.pdf>.

⁴⁰ See New Zealand Ministry of Health, *Response to Your Request for Official Information* (Apr. 27, 2023), https://www.health.govt.nz/system/files/documents/information-release/h2023022566_response_letter.pdf.

⁴¹ *Id.*

inclusiveness and dignity for all”⁴²—and that the Ministry “has not advised any change to access to services for young people” in New Zealand.⁴³

E. Spain

In Spain, patients over the age of sixteen can validly consent to medical care, including gender-affirming healthcare.⁴⁴ Access to gender-affirming healthcare is generally available throughout the country for patients under the age of sixteen, and specific laws governing availability vary among the seventeen autonomous regions in the country. For example, in the Community of Madrid, adolescent patients have the right to treatment by pediatric physicians and to receive puberty blockers and hormone therapy upon the onset of puberty.⁴⁵ In the Region of Murcia, patients over twelve can access gender-affirming healthcare with consent of the minor’s legal representative.⁴⁶ Throughout Spain, gender-reassignment

⁴² *Id.*

⁴³ New Zealand Ministry of Health, *Response to Your Request for Official Information* (June 1, 2023), https://www.health.govt.nz/system/files/documents/information-release/h2023024782_response_-_proactive_release.pdf.

⁴⁴ See FRA European Union Agency for Fundamental Rights, *Access to Transgender Hormone Therapy*, <https://fra.europa.eu/en/publication/2017/mapping-minimum-age-requirements-concerning-rights-child-eu/access-transgender-hormone-therapy> (last visited Nov. 15, 2023).

⁴⁵ Spain Law 2/2016 (July 1, 2016) (Community of Madrid, Spain)

⁴⁶ Spain Law 8/2016 (May 27, 2016) (Region of Murcia, Spain).

surgery is prohibited before the age of majority.⁴⁷ Moreover, new national legislation also requires the government to develop trainings for healthcare providers on LGBTQ issues.⁴⁸

CONCLUSION

The Court should reverse and remand with instructions to grant Plaintiffs-Appellants' motion for a preliminary injunction.

Respectfully submitted,

/s/ Andrew Rhys Davies

ANDREW RHYS DAVIES

CHARLES C. BRIDGE*

EMILY BRODY-BIZAR*

ANNA MIZZI*

DUY NGUYEN*

WILMER CUTLER PICKERING

HALE AND DORR LLP

7 World Trade Center

250 Greenwich Street

New York, NY 10007

(212) 230-8800

andrew.davies@wilmerhale.com

November 16, 2023

(*) *application for admission forthcoming*

⁴⁷ FRA European Union Agency for Fundamental Rights, *Access to Sex Reassignment Surgery*, <https://fra.europa.eu/en/publication/2017/mapping-minimum-age-requirements-concerning-rights-child-eu/access-sex-reassignment-surgery> (last visited Nov. 15, 2023).

⁴⁸ Spain Law 4/2023, B.O.E. No. 51, art. 16 (Mar. 1, 2023) (Protection and Promotion of the Health of LGBTI People), <https://www.boe.es/buscar/act.php?id=BOE-A-2023-5366&p=20230301&tn=1#a1-8> (select “English” translation).

CERTIFICATE OF COMPLIANCE

Pursuant to Fed. R. App. P. 29(a)(4)(G) and 32(g)(1), the undersigned hereby certifies that this brief complies with the type-volume limitation of Fed. R. App. P. 29(a)(5) and 32(a)(7)(B).

1. Exclusive of the exempted portions of the brief, as provided in Fed. R. App. P. 32(f) and 10th Cir. R. 32, the brief contains 4,484 words.

2. The brief has been prepared in proportionally spaced typeface using Microsoft Word for Microsoft 365 in 14-point Times New Roman font. As permitted by Fed. R. App. P. 32(g)(1), the undersigned has relied upon the word count feature of this word processing system in preparing this certificate.

/s/ Andrew Rhys Davies

ANDREW RHYS DAVIES

November 16, 2023

ADDITIONAL CERTIFICATIONS

Pursuant to the Court's CM/ECF User's Manual, the undersigned hereby certifies the following:

1. All required privacy redactions have been made.
2. If required to file additional hard copies, the hard copies to be submitted to the court will be exact copies of the version submitted electronically.
3. This ECF submission was scanned for viruses with McAfee version 5.7.4.399 (updated continuously via McAfee management portal), and according to the program, the file is free of malware.

/s/ Andrew Rhys Davies

ANDREW RHYS DAVIES

November 16, 2023

APPENDIX A

Stonewall Equality Limited (“Stonewall”) has fought since 1989 to create transformative change in the lives of LGBTQ+ people across communities in the United Kingdom and around the world. Stonewall seeks to drive positive change in public attitudes and public policy, and to ensure that LGBTQ+ people can thrive throughout their lives by building deep, sustained change programs with the institutions that have the biggest impact on them. Stonewall’s work includes supporting legal efforts to ensure that trans young people have access to gender-affirming medical treatment.

The Swedish Federation for Lesbian, Gay, Bisexual, Transgender, Queer and Intersex Rights (“RFSL”) is a non-profit community organization that has been advocating for the rights of LGBTQIA persons in Sweden and internationally since its founding in 1950. RFSL engages support and educational services, political advocacy, lobbying initiatives, and community space in furtherance of its mission supporting LGBTQIA persons. Since 2001, RFSL has formally included transgender people within the communities it serves. RFSL’s key initiatives today include transgender rights advocacy, asylum rights, and family law.

RFSL Ungdom is a children’s and youth organization affiliated with RFSL. The organization works to ensure that all young people in Sweden, regardless of

sexual orientation, gender identity, gender expression or gender characteristics, have their human rights, as described in the U.N. Declaration of Human Rights and in the European Convention on Human Rights, fulfilled.

Transammans, a Swedish non-profit organization for trans people and relatives, works across all of Sweden to influence, support and educate.

Transammans is a strong voice in the public debate and an important driving force for creating better living conditions for trans people of all ages and people with thoughts about their gender identity.

Seta ry / Seta rf / Seta Lgbtiq Rights in Finland is a non-profit organization that has been advocating for the rights of LGBTI persons in Finland since its founding in 1974. Seta ry / Seta rf / Seta Lgbtiq Rights in Finland aims for an equal society and individual welfare that includes everyone, regardless of sexual orientation, gender identity and gender expression.

The Norwegian Organization for Sexual and Gender Diversity (“FRI”) is a membership-based nongovernmental organization with local chapters throughout Norway. FRI’s vision is a society free from harassment and discrimination based on sexual orientation, gender identity, and/or gender expression. FRI’s key activities include national-level advocacy for the rights of LGBTI people, building competency of government institutions and employees within different sectors (education, health, social welfare, justice) to include

LGBTI people in a non-discriminatory way, and engaging in international solidarity by partnering with LGBTI organizations in Europe, Asia and Africa. As a membership and community-based organization, FRI has firsthand experience of the impact that gender-affirming healthcare—or the lack thereof—has on transgender people, and has deep concern that the State Healthcare Bans, by restricting access to gender-affirming care, will be detrimental to the lives of transgender people in Oklahoma.

The Australian Professional Association for Trans Health

(“**AusPATH**”) is Australia’s principal body representing, supporting, and connecting those working to strengthen the health, rights, and wellbeing of all transgender people—binary and non-binary. The AusPATH membership comprises over 350 experienced professionals working across Australia. AusPATH firmly believes that all young people who desire puberty suppression should be able to access such care in a timely manner under appropriate supervision and assessment by a multidisciplinary team. AusPATH advocates for access to timely, culturally safe, and person-centered gender-affirming healthcare as critical to protect transgender children, adolescents, and adults from negative health and well-being implications.

Bundesverband Trans* e.V. (“**BVT***”) is the largest transgender association in Germany. The association’s common endeavor is the commitment

to gender diversity and self-determination. BVT* is committed to human rights and to the respect, recognition, equality, social participation and health of transgender and non- binary people.

Fundación Colectivo Hombres XX, AC (the “Fundación”) is a non-profit community LGBTI organization with a particular focus on men in Mexico who were assigned a female gender at birth. The Fundación has operated since 2012 as a collective and since 2018 as a Civil Association and has extensive lobbying experience. The Fundación participated in the drafting of the Protocol for Access without Discrimination to Health Care Services for Lesbian, Gay, Bisexual, Transsexual, Transvestite, Transgender and Intersex Persons and Specific Care Guidelines, which provides guidance for the administration of healthcare to transgender individuals in Mexico.

The Professional Association for Transgender Health Aotearoa New Zealand (“PATHA NZ”) is an incorporated society established in May 2019 to be an interdisciplinary professional organization working to promote the health, well-being, and rights of transgender people. PATHA NZ comprises over 200 members who work professionally for transgender health in clinical, academic, community, legal, and other settings. As a society committed to supporting gender-affirming care, PATHA NZ’s role includes advocacy both within New Zealand and internationally. PATHA NZ views gender-affirming care for children and

adolescents as an essential part of healthcare and views the denial of access to care until the age of eighteen in any country or state as a violation of human rights.

The Federación Estatal de Lesbianas, Gais, Trans, Bisexuales, Intersexuales y más (“FELGTBI+”) is the largest LGTBI+ organization in Spain and one of the largest in Europe, with fifty-seven nongovernmental organizations and associations collaborating as member entities. It is one of only eight LGTBI+ organizations in the world that has consultative status with the United Nations. With thirty years of history, FELGTBI+ is one of the reference organizations in the promotion and defense of rights for LGTBI+ people. FELGTBI+’s mission is to defend and promote human rights and equality for lesbian, gay, transgender, bisexual, and intersex people and their families in all areas of life (social, health, work, educational, cultural, etc.). In addition, FELGTBI+ works to strengthen and unify the LGTBI associative movement in the Spanish territory from a networking approach and a secular, feminist, nonpartisan, and non-unionist perspective.

CERTIFICATE OF SERVICE

I hereby certify that on this 16th day of November, 2023, I electronically filed the foregoing with the Clerk of the Court for the United States Court of Appeals for the Tenth Circuit using the appellate CM/ECF system. Counsel for all parties to the case are registered CM/ECF users and will be served by the appellate CM/ECF system.

/s/ Andrew Rhys Davies

ANDREW RHYS DAVIES

November 16, 2023